Risk factors for side effects during first infusion of rituximab-definition of a low risk group (Q74234772)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Risk factors for side effects during first infusion of rituximab-definition of a low risk group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

H Hagberg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

E Holmbom

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

218-221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962533%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf02780531

9 November 2019

exact match

0 references

cites work

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

1 reference

12 December 2020

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020